CEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Urged to Contact the Firm

Core Viewpoint - Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. and AbbVie, Inc., raising concerns about the fairness of the transaction and the potential conflicts of interest among Cerevel's board of directors [4][5]. Group 1: Merger Details - On December 6, 2023, Cerevel Therapeutics announced its acquisition by AbbVie for $45.00 per share in cash, valuing the company at approximately$8.7 billion [8]. - The transaction has been approved by the boards of directors of both companies and is expected to close in mid-2024 [8]. Group 2: Legal Investigation - Bleichmar Fonti & Auld LLP believes that the board of directors of Cerevel Therapeutics was conflicted and engaged in an unfair process regarding the merger [5]. - Shareholders of Cerevel Therapeutics are encouraged to submit their information to explore their legal options related to the merger [6].